Netherlands· NL-c2a0223fbd3f
Cegfila 6 mg, oplossing voor injectie in voorgevulde spuit
A pegfilgrastim product containing pegfilgrastim, registered in Netherlands by Mundipharma Corporation (Ireland) Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pegfilgrastim is registered in 15 of 19 countries.
Countries holding a registration under ATC L03AA13 (pegfilgrastim), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Pegfilgrastim · ATC L03AA13
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pegfilgrastim costs, country by country.
Normalised to the WHO defined daily dose (0.3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pegfilgrastim · price per daily dose (0.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$69.77
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PEGFILGRASTIM
- Manufacturer
- Mundipharma Corporation (Ireland) Limited
- Country
- Netherlands (NL)
- ATC code
- L03AA13
- ATC class
- Pegfilgrastim
- Defined daily dose
- 0.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/19/1409
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
192 interactions on record for pegfilgrastim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pegfilgrastim · interactions on record
192 records
- 2 severe
- 190 moderate
Most severe, free to view
- CladribineL01BB04severe
- PegvaliaseA16AB19moderate
- CyclophosphamideL01AA01moderate
- ChlorambucilL01AA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pegfilgrastim in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceCEGFILA 6 mg, solution injectable en seringue préremplieMUNDIPHARMA CORPORATION (IRELAND)
- IrelandCegfila 6 mg solution for injection in pre-filled syringeMundipharma Corporation (Ireland) Limited
- FinlandCegfilaMundipharma Corporation (Ireland) Limited
- United StatesARMLUPEGLupin Pharmaceuticals, Inc.
- CzechiaCEGFILAMundipharma Corporation (Ireland) Limited, Dublin
- BelgiumCegfila 6 mgMundipharma Corporation
- PolandCegfilaMundipharma Corporation (Ireland) Limited
- SwedenCegfila 6 mg Injektionsvätska, lösning i förfylld sprutaMundipharma Corporation (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Pelmeg
- Iceland · Cegfila, Dyrupeg
- Liechtenstein · Cegfila, Dyrupeg
- Norway · Cegfila, Dyrupeg
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/59b08f81-b6da-4f1c-b323-93dbc814303e GET /v1/drugs/59b08f81-b6da-4f1c-b323-93dbc814303e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cegfila-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Pegfilgrastim",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125456",
"excipients": [
"NATRIUMACETAAT 3-WATER (E 262)",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 20 (E 432)",
"SORBITOL (E 420)",
"STIKSTOF (HEAD SPACE) (E 941)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"PEGFILGRASTIM"
],
"leaflet_url": null,
"authorised_at": "2019/12/19",
"procedure_number": "EMEA/H/C/005312",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/19/1409",
"additional_monitoring": "N"
}See everything about pegfilgrastim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.